Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol
- PMID: 1732074
- DOI: 10.1038/clpt.1992.3
Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol
Abstract
The N-demethylation of erythromycin and 6 beta-hydroxylation of cortisol are both functions of the glucocorticoid-inducible CYP3A in human liver microsomes. To determine whether 6 beta-hydroxylation and erythromycin N-demethylation are catalyzed by similar or distinct CYP3A isoforms, erythromycin N-demethylase activity, as reflected by the recently described 14[C]-erythromycin breath test, was compared with urinary 6 beta-hydroxycortisol/cortisol ratios, a measure of cortisol 6 beta-hydroxylase activity, in nine patients. Erythromycin N-demethylation varied fourfold and 6 beta-hydroxycortisol/cortisol ratios varied sevenfold among the subjects; no correlation was found between these activities (r2 = 0.065). New noninvasive tests of CYP3A strongly suggest cortisol 6 beta-hydroxylation and erythromycin N-demethylation are performed by distinct CYP3A isoforms.
Similar articles
-
Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men.Clin Pharmacol Ther. 1993 Dec;54(6):621-9. doi: 10.1038/clpt.1993.199. Clin Pharmacol Ther. 1993. PMID: 8275617
-
Hepatic cytochrome P-4503A (CYP3A) activity in the elderly.Mech Ageing Dev. 1992 Jun;64(1-2):189-99. doi: 10.1016/0047-6374(92)90106-n. Mech Ageing Dev. 1992. PMID: 1630156
-
Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A.Clin Pharmacol Ther. 1999 Sep;66(3):224-31. doi: 10.1016/S0009-9236(99)70029-9. Clin Pharmacol Ther. 1999. PMID: 10511057 Clinical Trial.
-
Noninvasive tests of CYP3A enzymes.Pharmacogenetics. 1994 Aug;4(4):171-84. doi: 10.1097/00008571-199408000-00001. Pharmacogenetics. 1994. PMID: 7987401 Review. No abstract available.
-
Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization.Clin Pharmacol Ther. 2001 Oct;70(4):305-10. Clin Pharmacol Ther. 2001. PMID: 11673745 Review. No abstract available.
Cited by
-
Verification of P-Glycoprotein Function at the Dermal Barrier in Diffusion Cells and Dynamic "Skin-On-A-Chip" Microfluidic Device.Pharmaceutics. 2020 Aug 25;12(9):804. doi: 10.3390/pharmaceutics12090804. Pharmaceutics. 2020. PMID: 32854319 Free PMC article.
-
Effects of obesity on pharmacokinetics implications for drug therapy.Clin Pharmacokinet. 2000 Sep;39(3):215-31. doi: 10.2165/00003088-200039030-00004. Clin Pharmacokinet. 2000. PMID: 11020136 Review.
-
Cytochrome P450 3A: ontogeny and drug disposition.Clin Pharmacokinet. 1999 Dec;37(6):485-505. doi: 10.2165/00003088-199937060-00004. Clin Pharmacokinet. 1999. PMID: 10628899 Review.
-
Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose.Br J Clin Pharmacol. 1995 Jun;39(6):611-20. doi: 10.1111/j.1365-2125.1995.tb05720.x. Br J Clin Pharmacol. 1995. PMID: 7654478 Free PMC article.
-
CYP3A5 polymorphism, amlodipine and hypertension.J Hum Hypertens. 2014 Mar;28(3):145-9. doi: 10.1038/jhh.2013.67. Epub 2013 Jul 18. J Hum Hypertens. 2014. PMID: 23863802 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources